Compare DexCom, Inc. (DXCM) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs MasTec Inc — how do they compare? DexCom, Inc. trades at $77.8 (market cap $28.06B), while MasTec Inc trades at $342.5 (market cap $28.27B). The key difference: DexCom, Inc. and MasTec Inc are close in size by market cap. Which is the better fit depends on your goals.
| DXCM | MTZ | |
|---|---|---|
Market Cap | $28.06B | $28.27B |
Sector | Health | Technology |
52-Week High | $89.53 | $437.51 |
52-Week Low | $54.84 | $172.51 |
Enterprise Value | $27.03B | $31.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
MasTec (MTZ) trades at $343.18, down 6% in the last session, amid a bearish technical signal. The stock shows strong fundamentals with Q1 2026 earnings beating estimates by 40.6% and a record $20.3 billion backlog. Recent news highlights a $1.65 billion acquisition of The Superior Group to expand AI data center infrastructure capabilities, driving investor optimism despite near-term price weakness.
Outlook remains positive with 88.9% analyst buy ratings and a $481.77 consensus target implying 40% upside. Key risks include execution of large acquisitions and integration challenges, while growth is supported by infrastructure spending trends in power, data centers, and clean energy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
